China-Only Studies Are ‘Problematic,’ US FDA’s Pazdur Says Ahead Of Lilly/Innovent PD-1 Inhibitor Review

 
• By Kate Rawson
  
Richard Pazdur speaks at BioPharma Congress in December 2021 (screenshot)
OCE Director Richard Pazdur wants China to join Project Orbis. • Source: screenshot
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D